Clinical trial · Interventional
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT00004070CI-TRIAL-00027084completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IL-12 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- IL-12 Injection 3mg/ml [Phase I]
- description
- The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
- interventionNames
- Biological: IL-12
- type
- EXPERIMENTAL
- label
- IL-12 Injection 6mg/ml [Phase I]
- description
- The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
- interventionNames
- Biological: IL-12
- type
- EXPERIMENTAL
- label
- IL-12 Injection MTD [Phase II]
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Females must be non-pregnant and non-lactating and either surgically sterile (via hysterectomy or bilateral tubal ligation), at least one year post-menopausal, or using acceptable methods of contraception for the duration of the study. * Male subjects must be surgically sterile or using an acceptable method of contraception for the duration of the study. * Disease: biopsy-proven unresectable or recurrent/refractory squamoussell\_eareinoma\_of\_the:head-and-neck-(usualLy -Stage-Di-or-IV) - * Tumor accessible to direct injection * Karnofsky performance of at least 70% * Life expectancy of at least three months * Able to give written informed consent Exclusion Criteria: * Infection (concurrent or within previous 2 weeks) * Active or clinically-relevant viral illnesses. * Use of corticosteroids, high-dose non-steroidal antiinflammatory, or immunosuppressive drugs * Chemotherapy, radiotherapy or immunotherapy within 28 days of study entry or during the course of study * Respiratory disease sufficient to influence oxygenation of arterial blood * Active liver disease with transaminases \>3 times the upper limit of normal * Previous history of liver disease * NYHA Class EU or greater heart failure * Serum creatinine of greater than 1.5 times the upper limit of normal * Polymorphonuclear neutrophilic leukocyte count \<3,000/mm3 * Platelet count \<50,000/mm 3 * Tumor involving major blood vessels or obstructing the airway * Previous treatment with viral-based gene therapy, recombinant DNA products, or bacterial plasmids * Use of an investigational drug within 30 days of screening * Other malignancies requiring treatment during the study * Scheduled surgical resection * History of autoimmune disease, including rheumatic disease, Crohn's disease, etc. , * Known allergy to polyvinylpyrrofidone (PVP) or related products * History of psychiatric disabilities or seizures.
References
Publications (0)
Data not yet available
No reference posted for this study.